Small airway dysfunction and associated clinical characteristicsin severe asthma under omalizumab and mepolizumab treatment
Small airway dysfunction (SAD) plays a critical role in the pathophysiology of asthma.
Drug persistence of omalizumab, cyclosporine,and hydroxychloroquinein antihistamine-refractory chronic spontaneous urticaria: A biomarker-stratified real-world study
Real-world comparative data on alternatives to omalizumab for antihistamine-refractory chronic spontaneous urticaria (CSU) are limited, particularly in resource-constrained Asia-Pacific settings.
Severe allergic asthma: Does alexithymia interfere with omalizumab treatment outcome?
Alexithymia is among psychological factors reported to interfere with asthma management. Severe allergic asthma (SAA) is characterized by uncontrolled asthma despite maximal standard pharmacological treatment which can benefit from an add-on treatment with Omalizumab, an anti-IgE monoclonal antibody.
Depression scores change significantly after omalizumab treatment in patients with chronic spontaneous urticaria
Chronic spontaneous urticaria (CSU) is frequently associated with psychiatric comorbidities.
Efficacy of drug therapies in antihistamine refractory chronic spontaneous urticaria: Real life data
Omalizumab is a safe and effective treatment for antihistamine-refractory chronic spontaneous urticaria (CSU) but is insufficient in one-third of patients. For serious cases in which omalizumab is ineffective, cyclosporine or methotrexate may be preferred. Most drug trials in CSU have focused on omalizumab or cyclosporine monotherapy.
Efficacy and safety of omalizumab in patients with moderate-to-severe asthma: An analytic comparison of data from randomized controlled trials between Chinese and Caucasians
Omalizumab has > 15 years of real-world evidence of effectiveness in Caucasian patients. In August 2017, it was approved as an add-on therapy for the management of moderate-to-severe asthma in China.